Trump signs order raising Canada tariffs to 35% from 25%
Investing.com - Merck&Co (NYSE: MRK) reported first quarter EPS of $2.22, $0.08 better than the analyst estimate of $2.14. Revenue for the quarter came in at $15.53B versus the consensus estimate of $15.63B.
Guidance
Merck&Co sees FY 2025 EPS of $8.82-$8.97 versus the analyst consensus of $8.94.
Merck&Co sees FY 2025 revenue of $64.10B-$65.60B versus the analyst consensus of $65.01B.
Merck&Co’s stock price closed at $78.74. It is down -17.59% in the last 3 months and down -39.76% in the last 12 months.
Merck&Co saw 2 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Merck&Co’s stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co’s Financial Health score is "great performance".
Check out Merck&Co’s recent earnings performance, and Merck&Co’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar